The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bayer
Research Funding - EMD Serono (Inst); Medpace (Inst); Momenta Pharmaceuticals (Inst); Onxeo (Inst); Pharmacyclics (Inst); Regeneron (Inst)
Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.
 
Kyriakos P Papadopoulos
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Onyx (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst)
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Eisai; Eisai; G1 Therapeutics; Lilly; MedImmune; Novartis; Sandoz; Seagen; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)
 
Melissa Johnson
Consulting or Advisory Role - Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Genentech/Roche (Inst); Otsuka (Inst)
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Stem Cells, Inc. (Inst)
 
Irene Brana
No Relationships to Disclose
 
Marta Gil Martin
No Relationships to Disclose
 
Raymond P. Perez
Consulting or Advisory Role - Pharmaceutical Research Associates
Research Funding - Agensys (Inst); Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Dompé Farmaceutici (Inst); Genentech/Roche (Inst); Immunogen (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Millennium (Inst); Novartis (Inst); Onyx (Inst); Regeneron (Inst); TetraLogic Pharmaceuticals (Inst)
 
Victor Moreno
No Relationships to Disclose
 
April K. Salama
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Abbvie (I); Bristol-Myers Squibb (Inst); Celldex (Inst); Dynavax Technologies (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Merck (Inst); Reata Pharmaceuticals (Inst)
 
Emiliano Calvo
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Lilly/ImClone; Nanobiotix; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Janssen Oncology; Lilly; Merck; Millennium; Nektar; Novartis; OncoMed; Pfizer; PharmaMar; PsiOxus Therapeutics; Puma Biotechnology; Roche/Genentech; Sanofi; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Lilly; Novartis; PsiOxus Therapeutics
Other Relationship - Pierre Fabre
 
Nelson S Yee
No Relationships to Disclose
 
Howard Safran
No Relationships to Disclose
 
Antonio Gonzalez Martin
Consulting or Advisory Role - PharmaMar; Roche
Speakers' Bureau - AstraZeneca; PharmaMar; Roche
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Raid Aljumaily
No Relationships to Disclose
 
Daruka Mahadevan
No Relationships to Disclose
 
Kosalai Kal Mohan
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Jingjin Li
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Elizabeth Stankevich
Employment - Regeneron
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene; Merck; Regeneron
 
Israel Lowy
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Consulting or Advisory Role - Egenix
Research Funding - AstraZeneca/MedImmune; Novartis; Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron (I)
 
Jade Homsi
Honoraria - Genentech; Merck
Consulting or Advisory Role - Castle Biosciences (Inst); Novartis (Inst)
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Genentech; Merck; Novartis